AVRO 1330% upside potential according to this analyst!!!

AVROBIO is a clinical-stage gene therapy company to treat rare diseases following a single dose worldwide.

AVRO just released positive data on their Phase 1/2 trial testing the safety and efficacy of AVR-RD-04.

73.42% of the shares are controlled by institutional investors, which gives me a lot of trust in the company.
JPMorgan Chase and BlackRock Inc. have the largest stakes in the company with an average around $9 per share.

On 1/5/2022 Barclays brokerage Boosted the Price Target of AVRO from $6.00 to $22.00.

The stock is now at all time low: $1.65.
the MARKET CAP is only 71.978Mil
I think it can be an easy buyout at this point.

What are we waiting for?